For research use only. Not for therapeutic Use.
SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival[1][2].
SBI-425 treatment suppresses Foxp3 expression in CD4+ and CD8+ T cells in splenocytes from CLP-injured mice[3].
1.19
Mouse PK parameters for SBI-425[1]
Compds
SBI-425
Clp (mL/min/kg)
5.14
Vd (L/kg)
1.03
Cmax (μg/mL)
178
AUC (μg*hr/mL)
848
t1/2 (hr)
2.3
%F
58
| Catalog Number | I018122 |
| CAS Number | 1451272-71-1 |
| Synonyms | 5-[(5-chloro-2-methoxyphenyl)sulfonylamino]pyridine-3-carboxamide |
| Molecular Formula | C13H12ClN3O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H12ClN3O4S/c1-21-11-3-2-9(14)5-12(11)22(19,20)17-10-4-8(13(15)18)6-16-7-10/h2-7,17H,1H3,(H2,15,18) |
| InChIKey | SBAITEDLNTYIOE-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C(C=C1)Cl)S(=O)(=O)NC2=CN=CC(=C2)C(=O)N |
| Reference | [1]. Pinkerton AB, et al. Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett. 2018 Jan 1;28(1):31-34. [2]. Sheen CR, et al. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res. 2015 May;30(5):824-36. [3]. Brichacek AL, et al. Systemic inhibition of tissue-nonspecific alkaline phosphatase alters the brain-immune axis in experimental sepsis. Sci Rep. 2019 Dec 11;9(1):18788. |
